Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Zalcitabine

FDA-approved product (tablet, oral), marketed as Hivid.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Zalcitabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF03

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Zalcitabine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Zalcitabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Zalcitabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment

    NCT00002334

    Registered record
    Registry ID
    NCT00002334
    Conditions
    HIV Infections
    Interventions
    Saquinavir; Zidovudine; Zalcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionSaquinavir; Zidovudine; Zalcitabine
    PhasePhase 3
    Registry statusCompleted

  • A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

    NCT00002367

    Registered record
    Registry ID
    NCT00002367
    Conditions
    HIV Infections
    Interventions
    Saquinavir; Lamivudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionSaquinavir; Lamivudine; Zidovudine
    PhasePhase 3
    Registry statusCompleted

  • Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

    NCT00021463

    Registered record
    Registry ID
    NCT00021463
    Conditions
    HIV Infections; Lipodystrophy
    Interventions
    Abacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    342

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Lipodystrophy
    InterventionAbacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
    PhasePhase 2
    Registry statusCompleted

  • Increasing HAART-Induced Immune Restoration With Cyclosporine

    NCT00031070

    Registered record
    Registry ID
    NCT00031070
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate, Lamivudine and Zidovudine; Cyclosporine; Hepatitis A Vaccine (Inactivated); Efavirenz; Pneumococcal Conjugate Vaccine, Heptavalent; Rabies Vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2006-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate, Lamivudine and Zidovudine; Cyclosporine; Hepatitis A Vaccine (Inactivated); Efavirenz +2 more
    PhasePhase 2
    Registry statusCompleted

  • An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B

    NCT00124241

    Registered record
    Registry ID
    NCT00124241
    Conditions
    Hepatitis B
    Interventions
    telbivudine; lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2005-11
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    Interventiontelbivudine; lamivudine
    PhasePhase 2
    Registry statusCompleted